Etoposide (Vepesid)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV, PO
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code names: VP-16, VP-TEC, VP 16213
  • Generic name: etoposide phosphate
  • Brand names:
Synonyms
Aside Beposid Bioposide Celltop Citodox Epocin Eposid Eposide
Eposido Eposin Epsidox ETO Etocris Etomedac Etonolver Etopofos
Etopophos Etopos Etoposid Etoposido Etopoxan Etopul Etosid Etosin
Eunades CS Euvaxon Exitop Fytop Fytosid Labimion Lastet Lastet S
Neoplaxol Nexvep Onkoposid Optasid Percas Posid Posidon Posyd
Riboposid Sintopozid Toposar Toposide Toposin Topresid Tosuben Vepefos
Vepeside Vepsid Vepside

References

  1. 1.0 1.1 Etoposide (Vepesid) package insert
  2. Etoposide (Vepesid) package insert (locally hosted backup)
  3. Etoposide (Vepesid) patient drug information (Chemocare)
  4. Etoposide (Vepesid) patient drug information (UpToDate)